April 25, 2018 09:23 AM EDT
R&D

Af­ter mega-round in­vest­ment, ADC Ther­a­peu­tics cans PhI tri­al in HER2

Brittany Meiling

Af­ter rais­ing a $200 mil­lion mega-round just months ago, Swiss drug­mak­er ADC Ther­a­peu­tics is ax­ing one of its pro­grams due to tox­i­c­i­ty is­sues.

The cut …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times